DURHAM, N.C.--Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that after discussion with the U.S. Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.
MENLO PARK, Calif.--Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium's President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference, Wednesday, February 11, 2015 at the Waldorf Astoria New York hotel.
MANCHESTER, Conn.--LYDALL, INC. (NYSE:LDL) announced today that it has completed the sale of Charter Medical, Ltd. ("Charter Medical"), a leading designer and manufacturer of specialty single-use products utilized in blood management, blood filtration and biopharmaceutical applications for the collection, processing, and storage of biological fluids.
JERSEY, Channel Islands--Quotient Limited ("Quotient") (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ending December 31, 2014 will be released after market close on Monday, February 2nd, 2015.
Stamford, CT--The SoldierSocks Advisory Board provides counsel on ways to better serve and assist members of the U.S. Armed Forces. In addition to Ms. MacCallum, the Advisory Board is comprised of former United States Senator Joseph Lieberman, Philanthropist John H. Linnartz, Former CEO Linda McMahon, Special Advisor to former Joint Chiefs of Staff and Secretary of State General Colin Powell, Colonel Bill Smullen, Dr. Kathleen H. Hicks and Retired Vice Admiral Bob Murrett.
SOUTH SAN FRANCISCO, Calif.--Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development.
SALT LAKE CITY--Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC") product candidate will be presented at the Society for Maternal-Fetal Medicine 35th Annual Meeting in San Diego, CA.
NEWTOWN, Pa.--Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced its participation in two investor conferences in February:
LEIDEN, The Netherlands--Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced today that it intends to voluntarily delist the registered shares of the Company, nominal value €0.01 per share (the "Shares"), from the NASDAQ Global Select Market ("NASDAQ").
NEW YORK--Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, announced today that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.
PHILADELPHIA--Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results.